Samuel Agresta

2.1k total citations
26 papers, 956 citations indexed

About

Samuel Agresta is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Samuel Agresta has authored 26 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Samuel Agresta's work include Acute Myeloid Leukemia Research (9 papers), Colorectal Cancer Treatments and Studies (4 papers) and Protein Degradation and Inhibitors (4 papers). Samuel Agresta is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Colorectal Cancer Treatments and Studies (4 papers) and Protein Degradation and Inhibitors (4 papers). Samuel Agresta collaborates with scholars based in United States, France and United Kingdom. Samuel Agresta's co-authors include Hatem Soliman, Courtney D. DiNardo, Martin S. Tallman, Eytan M. Stein, Stéphane de Botton, Gina Z. D’Amato, Daniel A. Pollyea, Eyal C. Attar, Robert H. Collins and Qiang Xu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Samuel Agresta

25 papers receiving 935 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Samuel Agresta United States	14	400	307	288	208	154	26	956
Fulya Ağaoğlu Türkiye	14	388 1.0×	163 0.5×	261 0.9×	317 1.5×	283 1.8×	46	930
C. Faul Germany	19	140 0.3×	396 1.3×	308 1.1×	187 0.9×	138 0.9×	67	1.4k
Simone Ferrero Italy	18	347 0.9×	390 1.3×	462 1.6×	176 0.8×	128 0.8×	82	1.3k
Suzanne Shusterman United States	23	645 1.6×	122 0.4×	642 2.2×	263 1.3×	384 2.5×	63	1.7k
Steve Nicholson United Kingdom	16	361 0.9×	79 0.3×	330 1.1×	132 0.6×	89 0.6×	34	994
Juliana Di Iulio Australia	16	318 0.8×	130 0.4×	645 2.2×	223 1.1×	81 0.5×	34	1.1k
Tomáš Skácel Switzerland	16	281 0.7×	343 1.1×	819 2.8×	249 1.2×	86 0.6×	33	1.0k
Han Myint United States	14	321 0.8×	305 1.0×	456 1.6×	193 0.9×	106 0.7×	30	1.1k
Robin E. Norris United States	14	325 0.8×	121 0.4×	211 0.7×	149 0.7×	75 0.5×	46	694
Nicola Di Renzo Italy	24	329 0.8×	531 1.7×	681 2.4×	277 1.3×	72 0.5×	98	1.9k

Countries citing papers authored by Samuel Agresta

Since Specialization

Citations

This map shows the geographic impact of Samuel Agresta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Agresta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Agresta more than expected).

Fields of papers citing papers by Samuel Agresta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Agresta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Agresta. The network helps show where Samuel Agresta may publish in the future.

Co-authorship network of co-authors of Samuel Agresta

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Agresta. A scholar is included among the top collaborators of Samuel Agresta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Agresta. Samuel Agresta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DiNardo, Courtney D., Michael R. Savona, Ashwin Kishtagari, et al.. (2023). Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies. Blood. 142(Supplement 1). 4284–4284. 10 indexed citations

Fan, Bin, David L. Dai, Courtney D. DiNardo, et al.. (2020). Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. Cancer Chemotherapy and Pharmacology. 85(5). 959–968. 22 indexed citations

Dai, David L., Hua Yang, Salah Nabhan, et al.. (2019). Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. European Journal of Clinical Pharmacology. 75(8). 1099–1108. 24 indexed citations

Pollyea, Daniel A., Martin S. Tallman, Stéphane de Botton, et al.. (2019). Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 33(11). 2575–2584. 165 indexed citations

Dai, David L., Courtney D. DiNardo, Eytan M. Stein, et al.. (2018). Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study.. Journal of Clinical Oncology. 36(15_suppl). 2581–2581. 2 indexed citations

Abou‐Alfa, Ghassan K., Juan W. Valle, Robin Kate Kelley, et al.. (2018). ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 36(4_suppl). TPS545–TPS545. 6 indexed citations

Le, Kha, David L. Dai, Bin Fan, et al.. (2018). Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies. Blood. 132(Supplement 1). 1394–1394. 4 indexed citations

Stein, Eytan M., Richard M. Stone, Daniel A. Pollyea, et al.. (2017). Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time. Blood. 130. 1299–1299. 2 indexed citations

Pollyea, Daniel A., Martin S. Tallman, Stéphane de Botton, et al.. (2017). Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2) Acute Myeloid Leukemia (AML). Blood. 130(Suppl_1). 638–638. 13 indexed citations

10.

Lowery, Maeve A., Ghassan K. Abou‐Alfa, Juan W. Valle, et al.. (2017). ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 35(15_suppl). TPS4142–TPS4142. 11 indexed citations

11.

Stein, Eytan M., Courtney D. DiNardo, Daniel A. Pollyea, et al.. (2017). Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.. Journal of Clinical Oncology. 35(15_suppl). 7004–7004.

12.

Lowery, Maeve A., Ghassan K. Abou‐Alfa, Howard A. Burris, et al.. (2017). Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.. Journal of Clinical Oncology. 35(15_suppl). 4015–4015. 73 indexed citations

13.

Yen, Katharine, René M. Lemieux, Janeta Popovici-Müller, et al.. (2013). IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model. Blood. 122(21). 3946–3946. 13 indexed citations

14.

DiNardo, Courtney D., Kathleen J. Propert, Alison W. Loren, et al.. (2013). Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 121(24). 4917–4924. 146 indexed citations

15.

Reynolds, Joseph G., Elena Geretti, Bart S. Hendriks, et al.. (2012). HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicology and Applied Pharmacology. 262(1). 1–10. 93 indexed citations

16.

Gupta, Manish, Patricia LoRusso, Bei Wang, et al.. (2011). Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2‐Targeted Antibody‐Drug Conjugate, in Patients With HER2‐Positive Metastatic Breast Cancer. The Journal of Clinical Pharmacology. 52(5). 691–703. 56 indexed citations

17.

Agresta, Samuel, Carlos E. Vigil, Xiuhua Zhao, et al.. (2010). Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. International Journal of Cancer. 129(8). 1963–1969. 91 indexed citations

18.

Bui, Marilyn M., et al.. (2008). Practical Issues of Intraoperative Frozen Section Diagnosis of Bone and Soft Tissue Lesions. Cancer Control. 15(1). 7–12. 37 indexed citations

19.

Soliman, Hatem & Samuel Agresta. (2008). Current Issues in Adolescent and Young Adult Cancer Survivorship. Cancer Control. 15(1). 55–62. 87 indexed citations

20.

Angela, C., et al.. (2007). Rhabdomyosarcoma of the Maxillary Gingiva. Journal of Periodontology. 78(9). 1839–1845. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact